Jyoti Nangalia is a CRUK Clinician Scientist at the Wellcome Sanger Institute. Her research group focuses on using sequencing technologies to understand the evolution of haematological cancers, with an emphasis on understanding how early myeloid neoplasms originate and evolve and how this relates to normal development and ageing. During her PhD she discovered mutations in Calreticulin in MPN that lacked mutations in JAK2 which has led to improved diagnosis for patients. She is a Consultant Haematologist and treats patients with myeloproliferative neoplasms. She is a member of the MPN clinical study subgroup of the National Cancer Research Institute and has contributed to the writing of national guidelines for MPN in the UK.